Cell Gene Therapy Clinical Trials Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The cell and gene therapy clinical trials market encompasses the research and development activities required to bring innovative cellular and genetic medicines through clinical testing phases. As of 2025, the global market is valued at approximately $13.47 billion, with projections indicating sustained expansion driven by the increasing number of therapies in clinical development. This segment represents the operational and service-oriented infrastructure supporting clinical investigations, including trial design, patient recruitment, monitoring, and data management specific to these complex biological treatments.

• •The broader cell and gene therapy market reached approximately $22.30 billion in 2025, while the gene therapy segment alone was valued at around $7.88 billion
• •The U.S. market accounts for approximately $5.41 billion of the global total, reflecting concentrated clinical activity in North America
• •Market size figures are based on industry analysis and projections from multiple market research assessments

Rising prevalence of genetic disorders and chronic diseases, combined with expanding clinical pipelines across oncology, rare diseases, and autoimmune conditions, is fueling substantial growth in clinical trial activity. Regulatory agencies have established accelerated approval pathways and orphan drug designations that reduce development timelines and incentivize investment in novel cell and gene therapies. Additionally, increased venture capital funding, corporate partnerships, and successful commercial launches of approved therapies have validated the sector, encouraging further pipeline expansion.

• •Breakthrough therapy designations and accelerated approval pathways have shortened development timelines for qualifying therapies
• •Rising prevalence of oncology and rare genetic disorders has expanded addressable patient populations for gene and cell therapies
• •Successful commercial launches of approved cell and gene therapies have demonstrated viable return on R&D investment

The market spans multiple therapeutic areas, with oncology representing the largest clinical trial segment, followed by rare genetic disorders, cardiovascular conditions, and neurological diseases. North America dominates regional activity, supported by advanced healthcare infrastructure, regulatory support from the FDA, and concentrated biopharmaceutical development hubs. Europe and Asia-Pacific are experiencing growing clinical trial volumes, driven by expanding patient registries, regulatory harmonization efforts, and investment in biotechnology ecosystems across the region.

• •North America leads regional market share, with the U.S. segment alone valued at approximately $5.41 billion in 2025
• •Oncology represents the dominant therapeutic area for cell and gene therapy clinical trials
• •Asia-Pacific markets are growing rapidly as regional regulatory frameworks become more supportive of advanced therapy development

What are the recent trends and outlook?

The market is expected to continue robust growth through the early 2030s as novel technologies such as CRISPR-based gene editing, CAR-T cell therapies, and in vivo gene therapies advance through clinical development. Increasing complexity of trial designs, including basket and umbrella trials, and the integration of real-world evidence are shaping how clinical trials are structured and monitored. Manufacturing scale-up challenges are driving investment in manufacturing clinical trial services, which is projected to grow at a compound annual growth rate of approximately 16.25%, reaching an estimated $26.59 billion by 2035.

• •CRISPR-based gene editing platforms and next-generation CAR-T therapies are advancing through late-stage clinical development
• •Manufacturing for clinical trials is emerging as a distinct and rapidly growing service segment
• •Integration of artificial intelligence and real-world evidence into clinical trial design is accelerating operational efficiency